LncRNA GAS8-AS1 is a Novel Prognostic and Diagnostic Biomarker for Pancreatic Cancer

Ling Zhang, Miao Li, Lihong Deng, DuJiang Yang, Chao Yue, Zhenlu Li, Weiming Hu, Huimin LüResearch 2021 · DOI

Abstract

Pancreatic cancer (PC) is a highly lethal malignancy often diagnosed at advanced stages due to its asymptomatic early progression. This study identifies the long non-coding RNA (lncRNA) GAS8-AS1 as a potential "liquid biopsy" biomarker. Analysis of 68 PC patients and 62 healthy controls revealed that plasma GAS8-AS1 levels are significantly lower in PC patients. This downregulation effectively distinguishes early-stage PC from healthy controls and correlates with poor 5-year survival. Furthermore, GAS8-AS1 interacts with miR-1179 in a positive feedback loop to inhibit tumor cell migration and invasion.

Introduction

Pancreatic cancer remains a significant clinical challenge with a five-year survival rate below 5%. Because current diagnostic tools often fail to catch the disease early enough for radical treatment, researchers are searching for reliable molecules circulating in the blood that can signal the presence of a tumor. GAS8-AS1, an lncRNA known to inhibit thyroid carcinoma, was investigated here to determine if it plays a similar defensive role in the pancreas.

Methods

The study cohort included 68 PC patients (stages I-IV) and 62 healthy volunteers. Plasma levels of GAS8-AS1 and miR-1179 were quantified using real-time quantitative PCR (qRT-PCR). Functional roles were assessed in pancreatic cancer cell lines (Capan-2 and HPAF-II) through transient transfection and Transwell migration/invasion assays. Diagnostic performance was evaluated using Receiver Operating Characteristic (ROC) curves, and prognostic value was assessed via 5-year overall survival analysis.

Key Results

Downregulation and Diagnostic Potential

Plasma GAS8-AS1 levels were significantly lower in PC patients compared to healthy controls. Notably, this downregulation was observed even in Stage I and II patients, making it a candidate for early-stage screening. ROC curve analysis demonstrated that GAS8-AS1 levels could distinguish PC patients from controls with an Area Under the Curve (AUC) of 0.87, indicating high diagnostic potential.

Figure 1: (A) Relative GAS8-AS1 expression levels in PC patients (n=68) versus healthy controls (n=62). (B) ROC curve analysis showing the sensitivity and specificity of GAS8-AS1 as a diagnostic marker.

Prognostic Value and Tumor Suppression

Low plasma levels of GAS8-AS1 were significantly associated with reduced 5-year overall survival (p = 0.037). In vitro experiments showed that overexpressing GAS8-AS1 or miR-1179 significantly inhibited the migration and invasion of Capan-2 and HPAF-II cells. When both were overexpressed, the inhibitory effect was even more pronounced, roughly halving the normalized cell migration compared to controls.

The GAS8-AS1/miR-1179 Feedback Loop

Interestingly, the study found that GAS8-AS1 and miR-1179 positively regulate each other. Transfecting cells with GAS8-AS1 led to an increase in miR-1179, and vice versa. This positive feedback loop creates a reinforced tumor-suppressive environment that limits the metastatic capabilities of PC cells.

Conclusion

GAS8-AS1 serves as a promising non-invasive biomarker for the early diagnosis and prognosis of pancreatic cancer. Its interaction with miR-1179 highlights a novel regulatory mechanism that could be targeted for future therapeutic strategies to improve patient outcomes.

Summary updated

Abstract

Abstract Background: LncRNA GAS8-AS1 inhibits thyroid carcinoma, but its function in other malignancies is unknown. The present study aimed to investigate the involvement of GAS8-AS1 in pancreatic cancer (PC). Methods: The present study included 68 PC patients (38 males and 30 females, 42- 66 years, 52.1±4.5) and 62 healthy volunteers (28 males and 24 females, 43- 67 years, 52.3 ±4.9). Real-time quantitative PCR, transient cell transfection and in vitro cell migration and invasion assay were applied for the research. In the present study we found that plasma GAS8-AS1 was lower in PC patients than in healthy controls. Downregulation of plasma GAS8-AS1 distinguished early stage PC patients from healthy controls. Results: Patients with low plasma levels of GAS8-AS1 showed significantly lower 5-year overall survival rate. Plasma levels of miR-1179 were also significantly lower in PC patients than in healthy controls, and were positively correlated with plasma levels of GAS8-AS1 only in PC patients. GAS8-AS1 overexpression resulted in the upregulation of miR-1179. MiR-1179 overexpression also led to the overexpression of GAS8-AS1. Overexpression of both GAS8-AS1 and miR-1179 led to inhibited migration and invasion of PC cells. Conclusions: Therefore, GAS8-AS1 may promote PC by positively interacting with miR-1179.
BibTeX
@inproceedings{zhang2021lncrna,
  author = {Ling Zhang and Miao Li and Lihong Deng and DuJiang Yang and Chao Yue and Zhenlu Li and Weiming Hu and Huimin Lü},
  title = {{LncRNA GAS8-AS1 is a Novel Prognostic and Diagnostic Biomarker for Pancreatic Cancer}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-154095/v1},
}
Figure